Tag Archives: GSK

Witty Touts GSK Pipeline in 4th Quarter Review

By Reid Paul | Published: February 10, 2012
brightcove.createExperiences();
Posted in Emerging Markets, Europe, Global, News, R&D, Strategy | Also tagged , , , , , | Leave a comment

Arise Sir Andrew (Witty)

By Guest Blogger | Published: January 4, 2012
Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Posted in Global, Op-Ed, leadership | Also tagged , , | Leave a comment

GSK's Andrew Witty: Further Concerns for Europe

By Julian Upton | Published: November 30, 2011
GSK’s Andrew Witty underlined his growing concerns with the business climate in Europe with his comments to the UK’s High Pay Commission last week. The Commission, set up by left-wing pressure group Compass, reported on the ‘corrosive’ effects of ‘boardroom excess’ and called for greater transparency in the setting of executive pay. The pay of [...]
Posted in Europe, Global, People, pricing | Also tagged , , , , | Leave a comment

It's Industry's Problem: A Fresh Take on R&D Costs

By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
Posted in Global, IP, R&D, leadership | Also tagged , , , | 2 Comments

Study Points to Dramatic Drop In R&D Expenditure

By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment